Aptamers: Trending Prospective in Therapeutics
DOI:
https://doi.org/10.47128/IJRDPL.2278-%200238.2019.8(5).1-9Keywords:
SELEX, Chemical antibody, Chronic diseases, Bio-production, TargetingAbstract
Aptamers are short stretches of Ribonucleic acid or Deoxyribonucleic acid having a specific 3D shape which form complexes with the target site with high affinity. Systemic Evolution of Ligands by Exponential Enrichment (SELEX) is responsible for the high affinity and specificity of aptamers to bind the target molecules. Due to some unique features of Aptamers, it attracts the attention of many scientists to use them as a tool in the treatment & diagnosis of various diseases and syndromes. The results obtained from the various clinical data shows that Aptamers can be used in the treatment and diagnosis of various diseases including cancer and syndromes like AIDS, severe acute respiratory syndrome etc. Many viral infections like human immunodeficiency virus, hepatitis B virus and Ebola virus are now treated or diagnosed with the help of aptamers. Along with viral infections, aptamers are also promising Chemical antibodies in the treatment of various kinds of cancer like breast cancer, lung cancer, colorectal cancer, etc. Aptamers have several advantages over conventional antibodies in context to its size, thermal stability, immunogenicity, ease of modification, etc. Aptamers are smaller than conventional antibodies, this property allows aptamers to access in tissue and cell. Aptamers are synthetic agents and we scale up its production as per requirement and it eliminate the various regulatory requirements associated with bio- production. The various roles of aptamers in the treatment and diagnosis of many life- threatening diseases, syndromes and viral infections like cancer, AIDS, Ebola virus lead aptamers to serve as Future Pharmaceutical dosage form or prospective Future of Modern Medical Science.
Downloads
References
Kyung MS, Seonghwan L, Changill B. Aptamers and Their Biological Applications. Sensors. 2012; 12: 612- 631.
Lakhin AV, Tarantul VZ, Gening LV. Aptamers: Problems, Solutions and Prospects. Acta Naturae. 2013; 5(4): 34-41.
Mascini M. Aptamers and their applications. Anal. Bioanal. Chem. 2008; 390: 987–988.
Birch J R, Rache A J. Antibody production. Adv. Drug. Deliv. Rev. 2006; 58: 671–685.
Ferreira CS, Missailidis S. Aptamer-based therapeutics and their potential in radiopharmaceutical design. Braz. Arch. Biol. Technol. 2007; 50: 63–76.
Jayasena S D. Aptamers: An emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 1999; 45: 1628–1650.
Ireson C R, Kelland L R. Discovery and development of anticancer aptamers. Mol. Cancer. Ther. 2006; 5: 2957– 2962.
Zhenjian Z, Yuanyuan Y, Maolin W, Jie L, Zongkang Z, Jin L, Xiaohao W. Recent Advances in SELEX Technlogy and Aptamer Applications in Biomedicine. Int. J. Mol. Sci. 2017; 18: 1-13.
Syed M A, Pervaiz S. Advances in aptamers. Oligonucleotides. 2010; 20: 215–224.
Bruno JG, Kiel JL. In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection. Biosens. Bioelectron. 1999; 14: 457–464.
Wan Y, Kim YT, Li, N, et al. Surface-immobilized aptamers for cancer cell isolation and microscopic cytology. Cancer. Res. 2010; 70: 9371–9380.
Li X, An Y, Jin J, Zhu Z, Hao L, Liu L, Shi Y, Fan D, Ji T, Yang CJ. Evolution of DNA aptamers through in vitro metastatic-cell-based systematic evolution of ligands by exponential enrichment for metastatic cancer recognition and imaging. Anal. Chem. 2015; 87: 4941– 4948.
Li X, Zhang W, Liu L, Zhu Z, Ouyang G, An Y, Zhao C, Yang, CJ. In vitro selection of DNA aptamers for metastatic breast cancer cell recognition and tissue imaging. Anal. Chem. 2014; 86: 6596–6603.
Song Y, Zhu Z, An Y, Zhang W, Zhang H, Liu D, Yu C, Duan W, Yang CJ. Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Anal. Chem. 2013; 85: 4141–4149.
Ji WK, Eun YK, Sun YK, et. al. Identification of DNA Aptamers Toward Epithelial Cell Adhesion Molecule via cell-SELEX. Mol Cells . 2014 Oct 31;37(10):742-6.
Wang Q, Liu W, Xing Y, Yang X, Wang K, Jiang R, Wang P, Zhao Q. Screening of DNA aptamers against myoglobin using a positive and negative selection unit integrated microfluidic chip and its biosensing application. Anal. Chem. 2014; 86: 6572–6579.
Bruno JG, Richarte AM, Phillips T, Savage AA, Sivils JC, Greis A, Mayo MW. Development of a fluorescent enzyme-linked DNA aptamer-magnetic bead sandwich assay and portable fluorometer for sensitive and rapid leishmania detection in sandflies. J. Fluoresc. 2014; 24: 267–277.
Cheung YW, Kwok J, Law AW, Watt RM, Kotaka M, Tanner JA. Structural basis for discriminatory recognition of plasmodium lactate dehydrogenase by a DNA aptamer. Proc. Natl. Acad. Sci. 2013; 110: 15967– 15972.
Charlton B, Crossley B, Hietala S. Conventional and future diagnostics for avian influenza. Comp. Immunol. Microbiol. Infect. Dis. 2009; 32: 341–350.
Luo Q, Huang H, Zou W, Dan H, Guo X, Zhang A, Yu Z, Chen H, Jin M. An indirect sandwich ELISA for the detection of avian influenza H5 subtype viruses using anti-hemagglutinin protein monoclonal antibody. Vet. Microbiol. 2009; 137: 24–30.
Dhumpa R, Handberg KJ, Jørgensen PH, Yi S, Wolff A, Bang DD. Rapid detection of avian influenza virus in chicken fecal samples by immunomagnetic capture reverse transcriptasepoly-merase chain reaction assay. Diagn. Microbiol. Infect. Dis. 2011; 69: 258–265.
Sidoti F, Rizzo F, Costa C, Astegiano S, Curtoni A, Mandola ML, Cavallo R, Bergallo M. Development of real time RT-PCR assays for detection of type A influenza virus and for subtyping of avian H5 and H7 hemagglutinin subtypes. Mol. Biotechnol. 2010; 44: 41– 50.
Yang J, Kim JH, Kim Y. Comparison of nine different qualitative HBsAg assay kits. Korean. J. Lab. Med. 2010; 30: 178–184.
Kim H, Shin S, Oh EJ, Kahng J, Kim Y, Lee HK, Kwon HJ. Comparison of the AdvanSure HBV real-time PCR test with three other HBV DNA quantification assays. Ann. Clin. Lab. Sci. 2013; 43: 230–237.
Muhlbacher A, Schennach H, Helden J, Hebell T, Pantaleo G, Bürgisser P, Cellerai C, Perm-pikul P, Rodriguez MI, Eiras A. Performance evaluation of a new fourth-generation HIV combination. Med. Microbiol. Immunol. 2013; 202: 77–86.
Saune K, Delaugerre C, Raymond S, Nicot F, Boineau J, Pasquier C, Izopet J. Analytical sensitivity of three real- time PCR assays for measuring subtype B HIV-1 RNA. J. Clin. Virol. 2013; 57: 80–83.
Tomasz W, Joanna W, Piotr K. Aptamers in Diagnostics and Treatment of Viral Infections. Viruses. 2015; 7: 751- 780.
Min K, Song KM, Cho M, et al. Simultaneous electrochemical detection of both PSMA (+) and PSMA (−) prostate cancer cells using an RNA/peptide dual- aptamer probe. Chem. Commun. 2010; 46: 5566–5568.
Bagalkot V, Zhang L, Levy-Nissenbaum E, et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano. Lett. 2007; 7: 3065–3070.
Kunii T, Ogura S, Mie M, et al. Selection of DNA aptamers recognizing small cell lung cancer using living cell-SELEX. Analyst. 2011; 136: 1310–1312.
Mi J, Liu YM, Rabbani ZN, et al. In vivo selection of tumor-targeting RNA motifs. Nat. Chem. Biol. 2010; 6: 22–24.
Ng EWM, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug. Discov. 2006; 5: 123-32.
Kourlas H, Schiller D S. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: A Review. Clinical. Ther. 2006; 28: 36-44.
Abhishek P. Aptamers in Therapeutics. JCDR. 2016; 10(6): 1-5.
Gang Z, George W, Lionel H, et al. Aptamers: A promising chemical antibody for cancer therapy. Oncotargets. 2015; 7(12): 13446-13458.
Muhammed A, Kwang G. Drug-target network. Nat. Biotechnol. 2007; 25: 1119-1126.
Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug. Discov. 2006; 5: 123-132.
Alvarez R H, Kantarjian H M, Cortes J E. Biology of plateletderived growth factor and its involvement in disease. Mayo. Clin. Proc. 2006; 81: 1241-1257.
Jo N, Mailhos C, Ju M, et al. Inhibition of plateletderived growth factor B signaling enhances the efficacy of anti- vascular enclothelial growth factor therapy in multiple models of ocular neovascularization. Am. J. Pathol. 2006; 168: 2036-2053.
Cahristdropher R I, Lloyd R K. Discovery and development of anticancer aptamers. Mol. Cancer. Ther. 2006; 5: 12-24.
Bates PJ, Laber DA, Miller DM, et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 2009; 86: 151-164.
Akiyama H, Kachi S, Silva RL, et al. Intraocular injection of an aptamer that binds PDGFB: a potential treatment for proliferative retinopathies. J. Cell. Physiol. 2006; 207: 407-412.
Sennino B1, Falcón BL, McCauley D, et al. Sequential loss of tumour vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer. Res. 2007; 67: 7358- 7366.
Kaur H, Li J J, Bay B H. Investigating the anti- proliferative activity of high affinity DNA aptamer on cancer cells. PLoS On 2013; 8: e50964.
Stacey LE, Vasanthanathan P, Jagat RK, et al. Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition. Chem. Commun. 2015; 51: 9499-9502.
Kwak H, Hwang I, Kim JH, et al. Modulation of transcription by the peroxisome proliferatoractivated receptor δ-binding RNA aptamer in colon cancer cells. Mol. Cancer. Ther. 2009; 8: 2664-2672.
Cahristdropher R I, Lloyd R K. Discovery and development of anticancer aptamers. Mol. Cancer. Ther. 2006; 5: 12-24.
Mongelard F, Bouvetety P. AS 1411, a guanosine rich oligo¬nucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr. Opin. Mol. Ther. 2010; 12: 107-114.
Vater A, Sahlmann J, Kroger N, et al. Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. Clin. Pharmacol. Ther. 2013; 94: 150-157.
Liu SC, Alomran R, Chernikova SB, et al. Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neuro. Oncol. 2014; 16: 21-28.
Hinterseer E. The spiegelmer NOX-A12 abrogates homing of human CLL cells to bone marrow and mobilizes murine CLL cells in the Eu-TCL1 transgenic mouse model of CLL. American Society of Hematology. 2013; 41: 11-16.
Hoellenriegel J, Zboralski D, Maasch C, et al. The spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood. 2014; 123: 1032-1039.
Chen CH, Chernis GA, Hoang VQ, et al. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc. Natl. Acad. Sci. 2003; 100: 9226- 9231.
Li N, Nguyen HH, Byrom M, et al. Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One. 2011; 6: e20299.
Esposito CL, Passaro D, Longobardo I, et al. A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS One. 2011; 6: e24071.
Wan Y, Tamuly D, Allen PB, et al. Proliferation and migration of tumor cells in tapered channels. Biomed. Micro. 2013; 15: 635-643.
Buerger C, Nagel WK, Kunz C, et al. Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J. Biol. Chem. 2003; 278: 37610- 37621.
Wang DL, Song YL, Zhu Z, et al. Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity. Biochem. Biophys. Res. Commun. 2014; 453: 681-685.
Jyoti B, Srinivasan C, Rajib KD, et. al. Aptamers in HIV research diagnosis and therapy.RNA Biol. 2018; 15(3): 327–337.
Victor MG, Elena MM, Geronima F, Ana GS. Use of Aptamers as Diagnostics Tools and Antiviral Agents for Human Viruses. Pharmaceuticals. 2016; 9(78): 1-24.
Partha R, Rebekah R.W. Aptamers for Targeted Drug Delivery. Pharmaceuticals (Basel). 2010 Jun; 3(6): 1761–1778.
Zhenjian Z, Yuanyuan Y, Maolin W, Jie L, Zongkang Z, Jin L, Xiaohao W. Recent Advances in SELEX Technlogy and Aptamer Applications in Biomedicine. Int. J. Mol. Sci. 2017; 18: 11.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
.